{"id":"NCT00459667","sponsor":"Bayer","briefTitle":"BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose","officialTitle":"International, Multicenter, Phase IIIb Study of Subcutaneous Every-other-day Treatment of Patients With Relapsing Multiple Sclerosis With (Phase A): Double-blind Betaseron/Betaferon 250µg or 500µg or Open-label Betaseron/Betaferon 250µg and (Phase B): Open-label Betaseron/Betaferon 500µg","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2008-03","completion":"2008-03","firstPosted":"2007-04-12","resultsPosted":"2009-08-17","lastUpdate":"2015-04-23"},"enrollment":1420,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis, Relapsing-Remitting"],"interventions":[{"type":"DRUG","name":"Interferon beta-1b (Betaseron, BAY86-5046)","otherNames":[]},{"type":"DRUG","name":"Interferon beta-1b (Betaseron, BAY86-5046)","otherNames":[]},{"type":"DRUG","name":"Interferon beta-1b (Betaseron, BAY86-5046)","otherNames":[]}],"arms":[{"label":"IFNB-1b 500 mcg","type":"EXPERIMENTAL"},{"label":"IFNB-1b 250 mcg","type":"EXPERIMENTAL"},{"label":"IFNB-1b 250 mcg*","type":"EXPERIMENTAL"}],"summary":"The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further investigate the safety and tolerability profile of interferon beta 1b 500µg during longer-term treatment.","primaryOutcome":{"measure":"Flu-like-syndrome","timeFrame":"309 days","effectByArm":[{"arm":"IFNB-1b 500 mcg","deltaMin":17.4,"sd":null},{"arm":"IFNB-1b 250 mcg","deltaMin":15.8,"sd":null},{"arm":"IFNB-1b 250 mcg*","deltaMin":31.1,"sd":null}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG001","p":null},{"comp":"OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":184,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Denmark","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Latvia","Netherlands","Norway","Poland","Russia","Slovenia","Spain","Sweden","Switzerland","Ukraine"]},"refs":{"pmids":["21952094"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":586},"commonTop":["Fatigue","Headache","Influenza like illness","Injection site reaction","Injection site erythema"]}}